News | News By Subject | News by Disease News By Date | Search News

Glioblastoma/Glioma News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Fortress Biotech (FBIO) Surged After Reporting Big Success With CAR-T Cancer Approach     12/30/2016
Glioblastoma Treatment Market Will Expand to $3.3 Billion by 2024, GlobalData Report Says     1/14/2016
Agenus (AGEN) Acquires PhosImmune in $44.9 Million Deal     12/29/2015
Celldex (CLDX) Cancer Vaccine Extends Life for Those With Brain Cancer     11/24/2015
Celsion (CLSN) Updates Clinical Trial Data and Slashes 20% of Workforce     9/9/2015
NW Bio (NWBO) Temporarily Halts Patient Screening for DCVax-L Brain Cancer Study     8/24/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
EXCLUSIVE: Experimental Cancer Drug From Oncoceutics Could Be Fast-Tracked, Says Exec     3/6/2015
EXCLUSIVE: Science "Finally Catching Up" With GBM Tumors, Says DelMar Pharmaceuticals CEO     2/27/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
AbbVie (ABBV) Touts Early Phase 1 Success With Brain Cancer Drug     6/2/2014
AngioChem's ANG1005 Received Fast Track And Orphan Drug Designation From FDA For The Treatment Of Glioblastoma Multiforme     5/30/2014
ImmunoCellular Therapeutics, Ltd (IMUC) Killed As Brain Cancer Drug Fails Key Phase 2 Study; Stock Down -59.56% At 10:12AM ET On Thursday     12/13/2013
EMD Serono Reports Disappointing Results for Cancer Drug Test     2/25/2013

News from Around the Web
Stock Tanks As NW Bio (NWBO) CTO Pleads Ignorance On Why Study Was Placed On Clinical Hold     4/5/2017
New Approach To Gene Therapy May Shrink Brain Tumors, Prevent Their Spread, Massachusetts General Hospital Neuroscience Center Study     9/26/2008
Brain Cancer Vaccine's Immune Response Key to Outcomes, Cedars-Sinai Study     7/16/2008
University of Alabama at Birmingham-Developed Glioma Drug Shows Promise in Phase 1 Trial     11/12/2007
Mayo Clinic Tests Novel Vaccine to Treat Aggressive Brain Tumors     10/24/2007
Genentech, Inc. (DNA)'s Avastin Seen As Helpful Against Deadly Brain Tumor     10/19/2007
University of California, San Francisco (UCSF) Brain Tumor Vaccine Trial Shows Promising Results     4/16/2007
Starve Brain Tumors Of Blood Shows Positive Results     1/22/2007
Cancer Immunoresistance Linked To Loss Of Tumor Suppressor Gene     12/11/2006
Brain Cancer Vaccine Made From Patients' Tumours     11/17/2006
Alkermes (ALKS) More Than A Drug Delivery Company     7/17/2006
Ark To File For Exceptional Approval Of Cerepro Gene Therapy     1/17/2005
Ark Therapeutics Raises £55M, Ends IPO Drought In London     3/10/2004

Press Releases
Athenex And Its Partner, Guangzhou Xiangxue Pharma, Announced Chinese FDA IND Approval To Begin Clinical Trials Of KX-02 Tablet For Glioblastoma     5/25/2017
ZIOPHARM Oncology (ZIOP) Announces Results Of Ad-RTS-hIL-12 + Veledimex In Recurrent Glioblastoma To Be Presented At The 2017 ASCO Annual Meeting     5/19/2017
VBL Therapeutics (VBLX) Presents Data On VB-111 In Combination With Checkpoint Inhibitor At The 20th Annual ASGCT Meeting     5/11/2017
DelMar Pharma Formalizes Collaboration With PRA Health Sciences For Phase III Trial Of VAL-083 In Recurrent Glioblastoma Multiforme (GBM)     5/11/2017
Carthera To Present Data From Phase I/IIa Study Focusing On Disrupting Blood-Brain Barrier For Treatment Of Recurring Glioblastoma At 2017 ASCO Annual Meeting     5/11/2017
DelMar Pharma Presents New Mechanism Of Action Data For Its Lead Agent VAL-083 In Temozolomide-Resistant Glioblastoma Multiforme (GBM) At The World Federation Of Neuro-Oncology Societies (WFNOS)     5/8/2017
Regeneron (REGN) And Inovio Pharma (INO) Enter Immuno-Oncology Clinical Study Agreement For Glioblastoma Combination Therapy     5/8/2017
Cantex Pharmaceuticals Announces Initiation Of Phase II Clinical Development For CX-02 In Recurrent Glioblastoma     5/1/2017
DelMar Pharma Collaborates With Duke University To Explore VAL-083 As A Front-Line Treatment For Glioblastoma Multiforme     4/25/2017
VBL Therapeutics (VBLX) Announces Positive DSMC Review in Phase III GLOBE Trial Investigating VB-111 in rGBM     4/21/2017
Medicenna Treats First Patient In Phase IIb Recurrent Glioblastoma Trial     4/13/2017
Nativis, Inc. Enters Into Exclusive Licensing Agreement For Glioblastoma Multiforme In Japan     4/4/2017
NovoCure Release: Combination Of Optune With Standard Of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates For Newly Diagnosed Glioblastoma Patients     4/3/2017
Bristol-Myers Squibb (BMY) Announces Results From Checkmate -143, A Phase III Study Of Opdivo (Nivolumab) In Patients With Glioblastoma Multiforme     4/3/2017
Massachusetts General Hospital/Dana Farber Initiate Expansion Of ONC201 Glioblastoma Trial     4/3/2017